针对BF.7、BQ.1.1和XBB.1的异源灭活病毒/信使核糖核酸疫苗接种反应 - Suppr

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1.

作者信息

Zuo Fanglei, Sun Rui, Abolhassani Hassan, Du Likun, Wang Yating, Vlachiotis Stelios, Bertoglio Federico, Schubert Maren, Rezaei Nima, Chavoshzadeh Zahra, Guerra Concetta, Cavalli Andrea, Andréll Juni, Kumagai-Braesch Makiko, Xue Yintong, Cao Yunlong, Hust Michael, Robbiani Davide F, Xie Xiaoliang Sunney, Hammarström Lennart, Marcotte Harold, Pan-Hammarström Qiang

机构信息

Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

Departments of Biotechnology and Medical Biotechnology, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Braunschweig, Germany.

出版信息

Lancet Reg Health West Pac. 2023 Apr;33:100762. doi: 10.1016/j.lanwpc.2023.100762. Epub 2023 Apr 12.

DOI:10.1016/j.lanwpc.2023.100762

PMID:37069895

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10092530/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab61/10130617/201b80e05fec/gr1.jpg

相似文献

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1.针对BF.7、BQ.1.1和XBB.1的异源灭活病毒/信使核糖核酸疫苗接种反应

Lancet Reg Health West Pac. 2023 Apr;33:100762. doi: 10.1016/j.lanwpc.2023.100762. Epub 2023 Apr 12.

Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.没完没了的故事？通过奥密克戎BQ.1、BQ.1.1、XBB和XBB.1变体的生物合成吉布斯自由能和抗原受体结合来监测新冠病毒的进化

Microb Risk Anal. 2023 Apr;23:100250. doi: 10.1016/j.mran.2023.100250. Epub 2023 Feb 3.

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.BQ.1.1、XBB.1 和 XBB.1.5 对癌症患者二价 mRNA COVID-19 加强针的中和作用。

Cancer Cell. 2023 Apr 10;41(4):649-650. doi: 10.1016/j.ccell.2023.02.003. Epub 2023 Feb 9.

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2.新型冠状病毒奥密克戎亚变体XBB.1.5、BQ.1、BQ.1.1、BF.7和BA.2.75.2的抗原特性

Signal Transduct Target Ther. 2023 Mar 15;8(1):125. doi: 10.1038/s41392-023-01391-x.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。

MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.

Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage.2022年10月至11月意大利SARS-CoV-2变体的废水监测：XBB.1、BA.2.75的检测以及BQ.1谱系的快速传播

Sci Total Environ. 2023 May 15;873:162339. doi: 10.1016/j.scitotenv.2023.162339. Epub 2023 Feb 21.

Can the RBD mutation R346X provide an additional fitness to the "variant soup," including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?新冠病毒奥密克戎毒株的受体结合域（RBD）突变R346X能否为“变异株混合体”（包括奥密克戎毒株的BQ和XBB亚变体的子代）提供额外的适应性以产生抗体抗性？

Mol Ther Nucleic Acids. 2023 Jun 13;32:61-63. doi: 10.1016/j.omtn.2023.02.030. Epub 2023 Mar 15.

Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.比较猪繁殖与呼吸综合征病毒（PRRSV）灭活疫苗与商品化疫苗对同源和异源攻毒的保护效果。

BMC Vet Res. 2012 Oct 3;8:182. doi: 10.1186/1746-6148-8-182.

Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy.意大利BQ.1.1.37新型冠状病毒亚谱系的出现

Diagnostics (Basel). 2023 Mar 6;13(5):1000. doi: 10.3390/diagnostics13051000.

Effect of IBV D1466 on egg production and egg quality and the effect of heterologous priming to increase the efficacy of an inactivated IBV vaccine.传染性支气管炎病毒D1466对产蛋性能和蛋品质的影响以及异源预处理对提高传染性支气管炎病毒灭活疫苗效力的影响。

Avian Pathol. 2020 Apr;49(2):185-192. doi: 10.1080/03079457.2019.1710462. Epub 2020 Jan 27.

引用本文的文献

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study.第二剂加强疫苗接种对奥密克戎变异株突破性感染临床结局的影响：一项倾向评分匹配队列研究。

Heliyon. 2023 Dec 7;10(1):e23344. doi: 10.1016/j.heliyon.2023.e23344. eCollection 2024 Jan 15.

Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines.分析已获批的 COVID-19 疫苗对奥密克戎变异株的保护效力和通用疫苗的前景。

Front Immunol. 2023 Nov 27;14:1294288. doi: 10.3389/fimmu.2023.1294288. eCollection 2023.

Design, structure and plasma binding of ancestral β-CoV scaffold antigens.祖先 β-CoV 支架抗原的设计、结构和血浆结合。

Nat Commun. 2023 Oct 16;14(1):6527. doi: 10.1038/s41467-023-42200-x.

Breakthrough SARS-CoV-2 Omicron Variant in Individuals Primed with Heterologous Vaccines Enhances Inhibition Performance of Neutralizing Antibody to BA.2 Parental Lineage.接种异源疫苗的个体中出现的新冠病毒奥密克戎突破性变异株增强了对BA.2原始谱系的中和抗体抑制性能。

Vaccines (Basel). 2023 Jul 11;11(7):1230. doi: 10.3390/vaccines11071230.

本文引用的文献

Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.对奥密克戎BA.4-BA.5二价加强针的抗体反应

N Engl J Med. 2023 Feb 9;388(6):567-569. doi: 10.1056/NEJMc2213907. Epub 2023 Jan 11.

Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.印迹 SARS-CoV-2 体液免疫诱导奥密克戎 RBD 进化趋同。

Nature. 2023 Feb;614(7948):521-529. doi: 10.1038/s41586-022-05644-7. Epub 2022 Dec 19.

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.奥密克戎变异株 BQ.1、BQ.1.1、BA.4.6、BF.7 和 BA.2.75.2 增强型中和抗性。

Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。

Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination.抗体反馈调节 SARS-CoV-2 mRNA 疫苗接种后的免疫记忆。

Nature. 2023 Jan;613(7945):735-742. doi: 10.1038/s41586-022-05609-w. Epub 2022 Dec 6.

Mucosal IgA against SARS-CoV-2 Omicron Infection.针对严重急性呼吸综合征冠状病毒2奥密克戎变异株感染的黏膜免疫球蛋白A

N Engl J Med. 2022 Nov 24;387(21):e55. doi: 10.1056/NEJMc2213153.

Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster.初次感染奥密克戎后交叉变异株中和作用有限：对含变异株加强针的考量

Signal Transduct Target Ther. 2022 Aug 22;7(1):294. doi: 10.1038/s41392-022-01146-0.

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.异源接种灭活疫苗后再接种 mRNA 加强针可诱导针对 SARS-CoV-2 奥密克戎变异株的强烈免疫应答。

Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.SARS-CoV-2 特异性 B 和 T 细胞反应在感染后 6-8 个月的 COVID-19 恢复期患者中持续存在。

Med. 2021 Mar 12;2(3):281-295.e4. doi: 10.1016/j.medj.2021.02.001. Epub 2021 Feb 10.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献